B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

FXN

MOLECULAR TARGET

frataxin

NCBI Gene: 23957 compounds

FXN (frataxin) is targeted by 7 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting FXN

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Demeclocycline1.393
2Dinitrochlorobenzene1.393
3kenpaullone1.393
4Vorinostat1.393
5Luteolin 5,7,3',4'-tetrahydroxy-flavone,0.691
6Disulfiram0.691
7Vanillic Acid0.691

About FXN as a Drug Target

FXN (frataxin) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 7 compounds with documented FXN interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

FXN inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.